Immunocore Holdings plc is a biotechnology business based in the US. Immunocore shares (IMCR) are listed on the NASDAQ and all prices are listed in US Dollars. Immunocore employs 291 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Immunocore
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IMCR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Immunocore stock price (NASDAQ: IMCR)Use our graph to track the performance of IMCR stocks over time.
Immunocore shares at a glance
|Latest market close||$22.95|
|52-week range||$26.00 - $61.99|
|50-day moving average||$34.90|
|200-day moving average||$36.16|
|Wall St. target price||$48.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.02|
Buy Immunocore shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Immunocore stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Immunocore price performance over time
|1 week (2022-01-10)||-18.85%|
|1 month (2021-12-17)||-28.39%|
|3 months (2021-10-15)||-39.61%|
|6 months (2021-07-16)||-35.44%|
|1 year (2021-01-13)||N/A|
|2 years (2020-01-13)||N/A|
|3 years (2019-01-13)||N/A|
|5 years (2017-01-13)||N/A|
|Revenue TTM||$27.3 million|
|Gross profit TTM||$30.1 million|
|Return on assets TTM||-32.05%|
|Return on equity TTM||-102.11%|
|Market capitalisation||$1.2 billion|
TTM: trailing 12 months
Immunocore share dividends
We're not expecting Immunocore to pay a dividend over the next 12 months.
Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom. .
Immunocore in the news
Immunocore (IMCR) presents at JP Morgan 40th Annual Virtual Healthcare Conference (Slideshow)
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Immunocore Holdings is Now Oversold (IMCR)
Frequently asked questionsWhat percentage of Immunocore is owned by insiders or institutions?
Currently 22.092% of Immunocore shares are held by insiders and 38.2% by institutions. How many people work for Immunocore?
Latest data suggests 291 work at Immunocore. When does the fiscal year end for Immunocore?
Immunocore's fiscal year ends in December. Where is Immunocore based?
Immunocore's address is: 92 Park Drive, Abingdon, United Kingdom, OX14 4RY What is Immunocore's ISIN number?
Immunocore's international securities identification number is: US45258D1054
More guides on Finder
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert